

Effective December 2019, the Board of Directors of Apyx Medical Corporation (the “Company”) approved amendments to the Company’s Code of Business Conduct and Ethics (the “Code”) to enhance, clarify and expand on certain aspects of the Code. The amendments to the Code include, among other things:

- The addition of the Company’s insider trading, management override controls, and conflict of interest policies;
- The inclusion of a reference to the Company’s recently implemented ethics hotline;
- The addition of an acknowledgement of the Company’s prohibition on retaliation; and
- Updates to certain roles and responsibilities to reflect the Company’s current organizational structure.